Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Autor:
Philippe Masson, Denis Moro-Sibilot, Isabelle Monnet, Anne-Claire Toffart, Bertrand Mennecier, Didier Debieuvre, E. Amour, Eric Pichon, Fabrice Barlesi, Olivier Molinier, Franck Morin, Patrick Aldo Renault, Anne Madroszyk-Flandin, Séverine Fraboulet, Isabelle Rouquette, Alexis B. Cortot, Pierre Jean Souquet, Virginie Westeel, Sandrine Hiret, Clarisse Audigier-Valette, Julien Mazieres, Benjamin Besse, Gérard Zalcman
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(13)
Purpose: The incidence of lung cancer has dramatically increased in women. Preclinical data have suggested that combining EGFR–tyrosine kinase inhibitor (TKI) with an antiestrogen may overcome resistance to EGFR-TKI. Patients and Methods: The IFCT-
Autor:
Keunchil Park, Myung-Ju Ahn, Sung Hee Lim, Kwai Han Yoo, Haa Na Song, Hae Su Kim, Jong Mu Sun, Yeon Hee Bae, Jiae Koh, Ji Yun Lee, Ki Sun Jung, Jin Seok Ahn, Se-Hoon Lee, Bo Mi Ku
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(9)
Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced non–small cell lung cancer (NSCLC) patients with acquired resistance to gefitinib or erlotinib. Experimental Design: In phas
Autor:
William Pao, Vincent A. Miller, Christopher G. Azzoli, Camelia S. Sima, Maria E. Arcila, Mark G. Kris, Yelena Y. Janjigian, Marc Ladanyi, Samantha Lindsay Kass, Gregory J. Riely, Geoffrey R. Oxnard
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(19)
Purpose: Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy. However, there are conflicting findings regarding the potential benefit of adjuvant
Autor:
Kyong-Ah Yoon, Tak Yun, Heung Tae Kim, Geon Kook Lee, Ji-Youn Han, Youngjoo Lee, Jin Soo Lee, Hyae Young Kim
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(15)
Purpose: Circulating cell-free DNA (CFDNA) was investigated as potential screening or prognostic markers in a variety of cancers. This study investigated its clinical significance in a homogeneous group of lung cancer patients. Experimental Design: W
Autor:
Hiroshi Nokihara, Tomohide Tamura, Ikuo Sekine, Masahiko Kusumoto, Hisao Asamura, Seiichiro Yamamoto, Yuichiro Ohe, Koh Furuta, Toshimi Takano, Noboru Yamamoto, Teruhiko Yoshida, Hideo Kunitoh, Masahiro Kaneko, Koji Tsuta, Takaaki Tsuchida, Hiromi Sakamoto, Tomoya Fukui
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(15)
Purpose: Epidermal growth factor receptor (EGFR) mutations, especially in-frame deletions in exon 19 (DEL) and a point mutation in exon 21 (L858R), predict gefitinib sensitivity in patients with non–small cell lung cancer (NSCLC). In this study, we
Autor:
Yih-Leong Chang, Pan-Chyr Yang, Chih-Hsin Yang, Jenn-Yu Wu, Shang-Gin Wu, Jin-Yuan Shih, Chien-Hung Gow, Chong-Jen Yu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(15)
Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited. To increase understanding of the influence of ex
Autor:
Chenghua Xia, Julian R. Molina, James R. Jett, Sumithra J. Mandrekar, Gary A. Croghan, Joel R. Reid, Randolph S. Marks, Chetan Lathia, Ronit Simantov, Lorelei J. Hanson, Alex A. Adjei
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(9)
Purpose: To evaluate the combination of sorafenib and gefitinib in patients with advanced non–small cell lung cancer. Experimental Design: In this dose-escalation trial, patients received oral sorafenib (200-400 mg) twice daily with gefitinib (250
Autor:
Thomas J. Lynch, Michael S. Rabin, David M. Jackman, Alison J. Holmes, Neal I. Lindeman, Daphne W. Bell, Daniel A. Haber, Beow Y. Yeap, Victoria A. Joshi, Matthew Meyerson, Pasi A. Jänne, Lecia V. Sequist, Bruce E. Johnson, Balazs Halmos, Mark S. Huberman
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(13)
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non–small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib. Our study explored the re
Autor:
Koji Tanaka, Fred R. Hirsch, Samir E. Witta, Anna E. Barón, Paul A. Bunn, Rafal Dziadziuszko, Wilbur A. Franklin, Peter V. Danenberg, Kathleen D. Danenberg, Seongjin Park, Federico Cappuzzo, Marileila Varella-Garcia, Lucio Crinò
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(10)
Purpose: Epidermal growth factor receptor (EGFR) mRNA expression and EGFR gene dosage by quantitative PCR in tumor samples obtained from patients with gefitinib-treated non–small cell lung cancer were analyzed in order to determine the association
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(23)
Purpose: Signal transducers and activators of transcription 3 (Stat3), a member of the STAT family of transcription factors, regulates multiple oncogenic pathways, including pathways regulating tumor cell survival. We evaluated Stat3 activation in ea